Oncology State Societies Advocacy Resources

Advocacy Aimed at Improving Access and Outcomes in Cancer Care: To address policies and practices that affect patient care and access, the Oncology State Societies (OSS) leads a policy and advocacy program focused on legislation and regulations impacting patient care and provider access. OSS has expanded its reach by collaborating with local and national organizations and state lobbyists to prioritize key legislative issues.

The OSS policy program has helped establish a policy communication and learning infrastructure in 15 participating states with over 130 engaged multidisciplinary providers across the US, demonstrating the collective power available to drive meaningful change. By collaborating to address key policy issues, OSS members can have a tangible impact on improving patient care and quality of life for both patients and caregivers.

To learn more about your state’s policy committee, email Lu Anne Bankert at lbankert@accc-cancer.org.

Town Hall Executive Summary

OSS Policy Town Hall

In September 2024, the Oncology State Societies held a Policy Committee Town Hall Meeting that brought together oncology professionals, lobbyists, and state society leaders to discuss key legislative and advocacy priorities impacting oncology care across the US. There were 83 total attendees, including the ACCC President-Elect and 55 members across 18 State Societies.

Discussions focused on:

  • Bipartisan support for cancer initiatives
  • Challenges with Medicaid and pharmacy benefit manager (PBM) reforms
  • State-level advocacy efforts such as prior authorization and biomarker testing
  • Patient and provider story collections
  • Strategies for effective lobbying and coalition-building

Gain strategies to utilize local lobbyists, build effective coalitions, and collaborate with other states to advance key federal- and state-level legislation and advocacy priorities.

Download Summary

The Advocacy Engagement Report provides OSS members with comprehensive case studies on issues that galvanized state societies to act. The report documents the specific actions taken by different state policy committees to affect change.

Read the report to:

  • Unlock the 6 keys to successful grassroots advocacy as found in this effort.
  • Learn how states without governmental affairs resources leveraged the power of their membership and their committee expertise.
  • Benefit from lessons learned.
  • Gain inspiration from a nationwide effort across OSS members to effect change.

Download Report

Engaging in advocacy through our state societies is one of the most direct ways we can have a voice in healthcare policies impacting the care of our patients.

Haley M. Simpson, MD, PhD
Chair, Policy Committee, Rocky Mountain Oncology Society

Cancer Buzz Podcasts

#AMCCBS: A Day on The Hill


February 29, 2024

The Association of Cancer Care Centers welcomed its members to Washington D.C for the ACCC 50th Annual Meeting & Cancer Center Business Summit (#AMCCBS) on Wednesday, February 28. This edition of #AMCCBS is different than any other as the Association debuted its new name and logo. These changes were made to represent the strength of its multidisciplinary membership and prepare ACCC for the next 50 years of innovation, education, and advocacy. This renewed dedication was communicated to members of the United States Congress when ACCC members traveled to Capitol Hill for the Association’s first in-person Hill Day in 5 years.

Understanding the importance and influence of policy to delivering comprehensive cancer care, ACCC concentrated its advocacy efforts on 4 integral issues that were identified by its membership and the patients they serve. They include:

  • Oncology Patient Navigation
  • Oncology Drug Shortages
  • Inflation Reduction Act
  • Financial Toxicity

Drug Shortages

“Therapies are so expensive, and we want to make sure we keep cancer care affordable and accessible to patients,” said Sarah Hudson-DiSalle, PharmD, RPh, assistant director of Infusion Reimbursement Services at the Arthur G. James Cancer Hospital at The Ohio State University, in a conversation with Matthew Williams, correspondence manager for Senator James David Vance (R-OH). “That takes everyone, and we want to ensure we are providing solutions for the issues the cancer care continuum faces.” Dr. Hudson Di-Salle explained to Williams that in 2023, the US experienced the highest rate of drug shortages in its modern history and expressed ACCC’s desire to develop a solution. “We want to fix it systematically….at the root of the cause and would like to partner with Senator Vance on some initiatives.” Willaims shared Dr. Hudson-Di-Salle’s desire to collaboratively develop initiatives that prevent or at the very least minimize the effects of future oncology drug shortages. “The system needs streamlined, coordinated communication processes... and I think we can have a fruitful relationship,” Williams said.  

Dr. Hudson-DiSalle and Matthew Williams

To address the oncology drug shortage, ACCC asks that Congress use its 40,000+ membership, as a resource. Further, ACCC requests that Congress identify, evaluate, and propose transparent policies to address future drug shortages when they occur.

Financial Toxicity + Patient Navigation

Among The Hill Day contingent were members of the Financial Advocacy Network (FAN) sub-committee. They shared compelling stories that highlighted the effects of financial toxicity and the expressed the need for patient navigation. Francinna Scott-Jones CPAR, ROCC, FACCC, financial coordinator, Northside Hospital Cancer Institute, Department of Radiation Oncology, met with Senator Raphael Warnock (D-GA), to discuss the out-of-pocket costs patients with cancer face during their initial diagnosis and treatment.

Financial Toxicity affects approximately 56% of patients with cancer. Considering that over half of cancer diagnoses occur in patients 66 years of age or older—a year before the normal retirement age—many patients may not have the income to combat its effects. Thus, ACCC encourages Congress to continue considering legislation that addresses the prevalence of financial toxicity across the cancer care continuum.

L-R: Molly Kisiel, MSN, FNP-BC, director of clinical content at ACCC, Sen. Warnock, and Francinna Scott-Jones. 

Other members of the FAN sub-committee shared the value of oncology patient navigation with Members of Congress. Angie Santiago, CRCS, senior business manager, Medical Oncology, Sidney Kimmel Cancer Center at Jefferson Health, and Aimee Hoch, MSW, LSW, OSW-C, oncology financial navigator, Grand View Health Cancer Center, met with the offices of Senator John Fetterman (D-PA), and Congressman Brendan Boyle of Pennsylvania’s 2ND district, to share their excitement for the new Healthcare Common Procedure Coding System patient navigation codes. These codes went into effect on January 1, 2024, and represent a historic new level of Medicare reimbursement for patient navigation services. They also had a chance encounter with Senator Cory Booker (D-NJ).

L-R: Aimee Hoch, Rifeta Kajdić-Hodžić, senior program manager, Oncology at ACCC, Angie Santiago, and Sen. Booker 

Inflation Reduction Act

President Joseph Biden signed the Inflation Reduction Act of 2022 (IRA) into law on August 16, 2022. The law contains multiple provisions aimed at reducing prescription drug prices and costs for patients. Further, it sought to lower prescription drug spending in the federal Medicare program. Some of the IRA’s drug pricing-related provisions include:

  • Medicare Part D Benefit Redesign with a Cap on Beneficiary Out-of-Pocket-Costs
  • Medicare Drug Price Negotiation Program (Medicare Part D Effective in 2026 and Part B Effective in 2028).
  • Rebates to Medicare: Pharmaceutical manufacturers must pay rebates to Medicare if prices for Medicare Part B or Part D rise faster than inflation.

ACCC believes the IRA’s Drug Pricing, Medicare Part D Benefit Redesign and Medicare Part B and D rebate provisions have the potential to provide real savings for Medicare beneficiaries. Consequently, ACCC asks that Congress, together with policymakers at the Department of Health and Human Services and the Center of Medicare and Medicaid Services, continue to listen to healthcare providers and patients as the implementation of the IRA moves forward.

In conclusion, ACCC members shared with their respective Congress people that the Association has endorsed the Protecting Patient Access to Cancer and Complex Therapies Act (S.2764/H.R.5391). This proposed legislation seeks to mitigate the impact of any reduced Medicare reimbursement under Medicare Part B on the providers and healthcare organizations that administer such therapies—including practices serving patients with cancer.

Capitol Hill Day marks the kickoff of the ACCC 50th Annual Meeting & Cancer Center Business Summit. Stay tuned to the ACCCBuzz blog for highlights from meeting sessions, and follow @ACCCBuzz on X for real-time updates and insights.

Our Supporter

Johnson-&-Johnson-460x80 

Participating States

TACOS-logo-200x90
RMOS-logo-200x90
HSCO-logo-250x266
IOS-IA-logo-200x90
Kentucky Society of Clinical Oncology Logo
LOS_v2_200px
MSCO-250x125
MOS-logo-200x90
NOS-logo-250x117
NMSCO-logo-190x60 
ESHOS-logo-200x90
NCOA-newlogo-220x100
TOPS-logo-250x117
SCOS-logo-200x90 
WAHO-385x247


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
tops-tennessee.com
Email Us